RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.


Regulatory Focus™ > News Articles > 10 > FDA’s OPDP Warns MannKind for Facebook Post

FDA’s OPDP Warns MannKind for Facebook Post

Posted 16 October 2018 | By Zachary Brennan 

FDA’s OPDP Warns MannKind for Facebook Post

The US Food and Drug Administration’s (FDA) Office of Prescription Drug Promotion (OPDP) earlier this month sent a warning letter to MannKind for a Facebook post that makes false or misleading claims about the risks associated with the company’s inhaled insulin, known as Afrezza.
“These violations are especially concerning from a public health perspective because Afrezza is a drug with multiple serious, potentially life-threatening risks, including a BOXED WARNING for the risk of acute bronchospasm in patients with chronic lung disease,” the warning letter says.
Specifically, the promotional Facebook post for Afrezza claims that the drug “will help your body work its best and protect you from health complications” with “no drama,” though FDA says that “may not be the case.”
“By suggesting that there are no risks associated with use of Afrezza, this post is misleading with respect to the drug’s safety,” FDA added. “We note the inclusion of the statement, ‘Please see full Prescribing Information, including boxed WARNING, Medication Guide, and Instructions for Use’ with a link to the PI in the post. However, this statement does not mitigate the misleading impression from the claims in the post.”
OPDP requests that MannKind immediately cease misbranding Afrezza or stop introducing the misbranded drug into interstate commerce.
“In order to clearly identify the violative promotional piece(s) and/or activity and focus on the corrective message(s), OPDP recommends that corrective piece(s) include a description of the violative promotional piece(s) and/or activity, include a summary of the violative message(s), provide information to correct each of the violative message(s), and be free of promotional claims and presentations. To the extent possible, corrective messaging should be distributed using the same media, and generally for the same duration of time and with the same frequency that the violative promotional material was disseminated,” the warning letter says.
Warning Letter
Promotional Material

Regulatory Focus newsletters

All the biggest regulatory news and happenings.


Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.